Results from the INBUILD trial show that nintedanib slowed lung function decline in patients with interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) by 57% across the overall study population over 52 weeks . Up to now, there are no treatment options for patients with non-IPF.
The tyrosine kinase inhibitor nintedanib is currently approved for the treatment of IPF as a result of the INPULSIS trials [2,3]. Some patients with ILDs other than IPF also develop a progressive fibrosing phenotype, characterised by an increasing extent of fibrosis on high-resolution computed tomography (HRCT), decline in lung function, worsening symptoms, and early mortality . Prof. Luca Richeldi (University of Southampton, United Kingdom) pointed out that preclinical studies have shown that nintedanib inhibits processes involved in the progression of fibrosis, irrespective of the trigger . This suggests that nintedanib may also reduce the progre...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Vaccines Show Multiple Positive Effects with Respect to Respiratory Health Next Article
Vaping Impairs Innate Immune Response of the Airway »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.